Anti-Inflammatory Peptides From Rice Can Be Mass-Produced in Bacteria and Fight Inflammation in Mice | Research

The takeaway

A rice-derived peptide was mass-produced in bacteria, shown to block the NF-κB inflammatory pathway, and validated in a mouse inflammation model — positioning it as a scalable functional food ingredient.

28.5 mg/L yield
The anti-inflammatory rice peptide PHP1 was produced in E. coli at commercially relevant levels, solving a key barrier to practical application of food-derived bioactive peptides

What the researchers found

Three anti-inflammatory peptides (PHP1, GPA1, GPD1) were identified from rice protein using receptor-based screening. The lead peptide PHP1 was successfully produced via recombinant expression in E. coli at 28.5 ± 3 mg/L using a fusion tag system. PHP1 significantly reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and nitric oxide in LPS-stimulated macrophages.

Mechanistically, PHP1 directly bound to NF-κB1 with a binding affinity of KD = 7.631 μmol/L and suppressed NF-κB1 phosphorylation — a key step in the inflammatory signaling cascade. The anti-inflammatory effect was validated in a mouse model of systemic inflammation.

Why it matters

Food-derived bioactive peptides are increasingly recognized as potential functional ingredients, but two barriers have limited their practical use: low natural abundance and high chemical synthesis costs. This study solves the production problem by showing that rice anti-inflammatory peptides can be efficiently manufactured using bacteria (E. coli), making large-scale production feasible. The identification of a specific molecular target (NF-κB1) elevates these from vaguely 'bioactive' to mechanistically characterized functional peptides.

The numbers in context

3 anti-inflammatory peptides identified · 28.5 mg/L recombinant yield · KD = 7.631 μmol/L (PHP1-NF-κB1 binding) · TNF-α, IL-1β, IL-6 reduced · Mouse inflammation model validated

How the study worked

Researchers used receptor-based computational screening to identify anti-inflammatory peptide candidates from rice protein. Three candidates were selected and the lead peptide (PHP1) was produced recombinantly in E. coli using a fusion tag expression system. Anti-inflammatory activity was tested in LPS-stimulated RAW264.7 macrophages measuring cytokine levels and nitric oxide. Binding to NF-κB1 was characterized by surface plasmon resonance. Efficacy was validated in a mouse model of systemic inflammation.

Who was studied

In vitro RAW264.7 macrophage studies; in vivo mouse systemic inflammation model

What this study cannot tell us

The study focused primarily on one lead peptide (PHP1), and the other two candidates (GPA1, GPD1) were less characterized. The mouse model used systemic inflammation rather than specific disease conditions where these peptides might be applied. Oral bioavailability and stability of the peptides in the digestive tract were not addressed — critical factors for functional food application. Human studies are needed to confirm anti-inflammatory effects.

How to read the evidence

This is a preclinical study with in vitro mechanistic data and in vivo mouse model validation. The mechanistic characterization (NF-κB1 binding) is rigorous, but the functional food application requires human studies confirming oral bioavailability and efficacy.

When this study was published

Published in 2026, this is very recent research at the forefront of food-derived peptide development, combining computational screening with modern biotechnology for scalable production.

The bigger picture

Food-derived bioactive peptides represent a growing intersection of nutrition science and drug development. The approach demonstrated here — computational screening, recombinant production, mechanistic characterization, and in vivo validation — sets a template for developing functional food peptides with pharmaceutical rigor. If PHP1 survives digestion and maintains activity when eaten (a key unanswered question), it could represent a new category of anti-inflammatory functional food.

Questions still open

Can PHP1 survive digestion and maintain anti-inflammatory activity when consumed orally as a food ingredient?
Would chronic dietary intake of PHP1 provide meaningful anti-inflammatory benefits in humans?
Could this recombinant production approach be applied to other food-derived bioactive peptides at commercial scale?

Common questions

What are food-derived bioactive peptides?

Bioactive peptides are short chains of amino acids hidden within food proteins (like rice, milk, or soy) that have beneficial health effects beyond basic nutrition. When these proteins are broken down — either during digestion or industrial processing — the peptides are released and can have anti-inflammatory, antioxidant, or blood pressure-lowering effects. The challenge is producing enough of them affordably.

How does producing peptides in bacteria help?

Instead of extracting tiny amounts of peptides from large quantities of rice or chemically synthesizing them (which is expensive), researchers engineered E. coli bacteria to act as tiny peptide factories. The bacteria read the peptide's genetic code and produce it in quantity — 28.5 mg per liter of bacterial culture. This approach is much more scalable and cost-effective for commercial functional food production.

Read the original research

An Integrated Strategy for the Discovery, Recombinant Expression, and Biological Evaluation of Anti-Inflammatory Peptides from Rice Protein.

Journal of agricultural and food chemistry, 74(7), 6243-6255

View on PubMed ↗Publisher’s paper ↗

Citation

Qu, Tingmin; Huang, Ruibo; Wu, Ying; Wu, Hao; Mu, Daichen; Duan, Yanting; Tan, Wenzhi; Huang, Qingming; Hu, Jian; Wen, Li. (2026). An Integrated Strategy for the Discovery, Recombinant Expression, and Biological Evaluation of Anti-Inflammatory Peptides from Rice Protein.. Journal of agricultural and food chemistry, 74(7), 6243-6255. https://doi.org/10.1021/acs.jafc.5c15308